Exendin-4 protects against sulfonylurea-induced β-cell apoptosis

Journal of Pharmacological Sciences

Volumn 118, Issue 1, 2012, Pages 65-74

  Kim, Ju Young ^a   Lim, Dong Mee ^a   Park, Hyung Seo ^a   Moon, Chan Il ^b   Choi, Kyung Jin ^a   Lee, Seong Kyu ^c   Baik, Haing Woon ^c   Park, Keun Young ^a   Kim, Byung Joon ^a  

^a Konyang University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Eulji University School of Medicine   (South Korea)

Author keywords

Apoptosis; Endoplasmic reticulum (ER) calcium depletion; ER stress; Glucagon like peptide 1(GLP 1); Sulfonylurea

Indexed keywords

CALCIUM ION; CASPASE 3; EXENDIN 4; GLIBENCLAMIDE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL ISOLATION; CELL LINE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FLOW CYTOMETRY; HAMSTER; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84863031805     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11072FP     Document Type: Article

References (36)

1. Sudhir R, Mohan V. Postprandial hyperglycemia in patients with type 2 diabetes mellitus. Treat Endocrinol. 2002;1:105-116. (Pubitemid 36828430)
2. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism. 2006;55:S20-S27.
3. Kawaki J, Nagashima K, Tanaka J, Miki T, Miyazaki M, Gonoi T, et al. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes. 1999;48:2001-2006. (Pubitemid 29458363)
4. Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J Diabetes Complications. 2002;16:123-132. (Pubitemid 34168514)
5. Iwakura T, Fujimoto S, Kagimoto S, Inada A, Kubota A, Someya Y, et al. Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun. 2000;271:422-428. (Pubitemid 30444742)
6. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501-506. (Pubitemid 40116700)
7. Takahashi A, Nagashima K, Hamasaki A, Kuwamura N, Kawasaki Y, Ikeda H, et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract. 2007;77:343-350. (Pubitemid 47211335)
8. Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes. 2002;51:S455-S461. (Pubitemid 35403430)
9. Scheuner D, Kaufman RJ. The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes. Endocr Rev. 2008;29:17-33.
10. Fonseca SG, Burcin M, Gromada J, Urano F. Endoplasmic reticulum stress in beta-cells and development of diabetes. Curr Opin Pharmacol. 2009;9:763-770.
11. Berridge MJ. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium. 2002;32:235-249. (Pubitemid 36175747)
12. Sammels E, Parys JB, Missiaen L, De Smedt H, Bultynck G. Intracellular Ca2+ storage in health and disease: a dynamic equilibrium. Cell Calcium. 2010;47:297-314.
13. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogues: new therapeutic agents for use in the treatment of diabetesmellitus. Curr Med Chem. 2003;10:2471-2483. (Pubitemid 37236400)
14. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113:546-593. (Pubitemid 46365961)
15. Kim MH, Lee MK. The incretins and pancreatic beta-cells: use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes mellitus. Korean Diabetes J. 2010;34:2-9.
16. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006;4:391-406. (Pubitemid 44752565)
17. Tsunekawa S, Yamamoto N, Tsukamoto K, Itoh Y, Kaneko Y, Kimura T, et al. Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. J Endocrinol. 2007;193:65-74.
18. Kim JY, Lee SK, Baik HW, Lee KH, Kim HJ, Park KS, et al. Protective effects of glucagon like peptide-1 on HIT-T15 β cell apoptosis via ER stress induced by 2-deoxy-D-glucose. Korean Diabetes J. 2008;32:477-487.
19. Kwon DY, Kim YS, Ahn IS, Kim DS, Kang S, Hong SM, et al. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J Pharmacol Sci. 2009;111:361-371.
20. Sutton R, Peters M, McShane P, Gray DW, Morris PJ. Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation. 1986;42:689-691. (Pubitemid 17210307)
21. Steensma DP, Timm M, Witzig TE. Flow cytometric methods for detection and quantification of apoptosis. Methods Mol Med. 2003;85:323-332.
22. 2+ release to ATP in pancreatic acinar cells. J Biol Chem. 2008;283:26081-26088.
23. Qian L, Zhang S, Xu L, Peng Y. Endoplasmic reticulum stress in beta cells: latent mechanism of secondary sulfonylurea failure in type 2 diabetes? Med Hypotheses. 2008;71:889-891.
24. Inoguchi T, Umeda F, Kakimoto M, Sako Y, Ishii H, Noda K, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J. 2000;47:763-770. (Pubitemid 32118490)
25. Dworacka M, Abramczyk M, Winiarska H, Kuczynski S, Borowska M, Szczawinska K. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. Int J Clin Pharmacol Ther. 2006;44:14-21. (Pubitemid 43085493)
26. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis. 2006;11:5-13. (Pubitemid 43151639)
27. 2+-ATPase-dependent apoptosis via mitochondrial pathway in PC12 cells. J Pharmacol Sci. 2004;95:33-40.
28. Wu KD, Lee WS, Wey J, Bungard D, Lytton J. Localization and quantification of endoplasmic reticulum Ca(2+)-ATPase isoform transcripts. Am J Physiol. 1995;269:C775-C784.
29. East JM. Sarco(endo)plasmic reticulum calcium pumps: recent advances in our understanding of structure/function and biology (review). Mol Membr Biol. 2000;17:189-200. (Pubitemid 32267316)
30. Váradi A, Molnár E, Ostenson CG, Ashcroft SJ. Isoforms of endoplasmic reticulum Ca(2+)-ATPase are differentially expressed in normal and diabetic islets of Langerhans. Biochem J. 1996; 319:521-527.
31. Araki E, Oyadomari S, Mori M. Impact of endoplasmic reticulum stress pathway on pancreatic beta-cells and diabetes mellitus. Exp Biol Med (Maywood). 2003;228:1213-1217. (Pubitemid 37413682)
32. 2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes. 2005;54:452-461.
33. Schildberg FA, Schulz S, Dombrowski F, Minor T. Cyclic AMP alleviates endoplasmic stress and programmed cell death induced by lipopolysaccharides in human endothelial cells. Cell Tissue Res. 2005;320:91-98. (Pubitemid 40543765)
34. Yaekura K, Yada T. [Ca2+]i-reducing action of cAMP in rat pancreatic beta-cells: involvement of thapsigargin-sensitive stores. Am J Physiol. 1998;274:C513-C521.
35. Koh GP, Suh KS, Chon S, Oh SJ, Woo JT, Kim SW, et al. The effect of cAMP-elevating agents on high glucose-induced apoptosis of isolated islets of rat pancreas. Korean Diabetes J. 2004; 28:490-500.
36. Grandoch M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol. 2010;159:265-284.